archived version — not current
This is a permanent, read-only archive of this profile's public content as it existed on 2026-09-23. It does not reflect the current, live profile. View the current profile.
Liraglutide
Snapshot captured 2026-09-23 — Published content materially edited
Overview
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist investigated in type 2 diabetes and weight management. WPF separates findings by dose, population, indication, comparator, and endpoint so that one result is not generalized to every setting.
Evidence quality
WPF’s existing Liraglutide research atlas includes directly attributable randomized studies: the LEADER cardiovascular outcomes trial in type 2 diabetes (PMID 27295427), a weight-management trial (PMID 26132939), and a pediatric obesity trial (PMID 39258838). It also includes a randomized comparison with semaglutide in weight management (PMID 35015037). These trials address distinct populations, regimens, and endpoints. A cardiovascular meta-analysis (PMID 37854744) is listed as a screening source, not a substitute for appraising the underlying trials.
Safety concerns
This Directory entry has not yet converted its screening inventory into a fully source-linked editorial synthesis. Diabetes and weight-management studies use different populations, doses, and outcomes; pediatric findings require their own context. The absence of published citations in this Directory lane reflects its workflow state, not the absence of research.
Content hash: 32d399b5635b0ff908e8ab572a27e142dba743f202b2a979865d060d3bd801b0